Drug-targeting strategies in cancer therapy.
Genetic changes in cell-cycle, apoptotic, and survival pathways cause tumorigenesis, leading to significant phenotypic changes in transformed cells. These changes in the tumor environment - elevated expression of surface proteases, increased angiogenesis and glucuronidase activity - can be taken advantage of to improve the therapeutic index of existing cancer therapies. Targeting cytotoxics to tumor cells by enzymatic activation is a promising strategy for improving chemotherapeutics.
Huang
P S
PS
Dupont Pharmaceuticals Co., Department of Cancer Research, Glenolden, Pennsylvania 19036, USA.
Oliff
A
A
D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D001839:Bombesin / Q000737:chemistry; D004317:Doxorubicin / Q000737:chemistry / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D010450:Endopeptidases / Q000737:chemistry; D005966:Glucuronidase / Q000737:chemistry; D007987:Gonadotropin-Releasing Hormone / Q000737:chemistry; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009842:Oligopeptides / Q000737:chemistry; D017239:Paclitaxel / Q000737:chemistry / Q000627:therapeutic use; D011355:Prodrugs / Q000737:chemistry / Q000627:therapeutic use*; D018000:Receptors, Peptide / Q000378:metabolism; D013004:Somatostatin / Q000737:chemistry
D000970:Antineoplastic Agents; D009842:Oligopeptides; D011355:Prodrugs; D018000:Receptors, Peptide; D007987:Gonadotropin-Releasing Hormone; D013004:Somatostatin; D004317:Doxorubicin; D005966:Glucuronidase; D010450:Endopeptidases; D017239:Paclitaxel; D001839:Bombesin